Myriad Genetics (MYGN) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $6.35 -4.8%
Revenue Growth %: -7.0%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
SYRS, ZVOI, OMID, More
Revenue Growth %: -7.0%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
SYRS, ZVOI, OMID, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter came in at $211 million versus the consensus estimate of $213.31 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kosmos Energy (KOS) Misses Q3 EPS by 3c
- Citi raises Weyerhaeuser price target to $23, keeps Buy rating
- Four Corners Property Trust (FCPT) PT Lowered to $26 at Citizens as JV, Buybacks Under Consideration
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
